Kidney Transplant Rejection – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Kidney Transplant Rejection – Pipeline Review, H2 2016’, provides an overview of the Kidney Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection

The report reviews pipeline therapeutics for Kidney Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kidney Transplant Rejection therapeutics and enlists all their major and minor projects

The report assesses Kidney Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kidney Transplant Rejection

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kidney Transplant Rejection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alexion Pharmaceuticals Inc

Amgen Inc.

Amyndas Pharmaceuticals LLC

Angion Biomedica Corp.

Apellis Pharmaceuticals Inc

Astellas Pharma Inc.

Bio-inRen

Biogen Inc

Catalyst Biosciences, Inc.

Corline Biomedical AB

CSL Limited

Digna Biotech, S.L.

GlaxoSmithKline Plc

Grifols, S.A.

Hansa Medical AB

Kyowa Hakko Kirin Co., Ltd.

Mabtech Limited

Magnus Life Ltd

Noorik Biopharmaceuticals AG

Novartis AG

Opsona Therapeutics Limited

OSE Immunotherapeutics

Pharmicell Co., Ltd.

Pharming Group N.V.

Prolong Pharmaceuticals, LLC

Quark Pharmaceuticals, Inc.

Shire Plc

Tiziana Life Sciences Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Kidney Transplant Rejection Overview 8

Therapeutics Development 9

Pipeline Products for Kidney Transplant Rejection - Overview 9

Pipeline Products for Kidney Transplant Rejection - Comparative Analysis 10

Kidney Transplant Rejection - Therapeutics under Development by Companies 11

Kidney Transplant Rejection - Therapeutics under Investigation by Universities/Institutes 13

Kidney Transplant Rejection - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Kidney Transplant Rejection - Products under Development by Companies 17

Kidney Transplant Rejection - Products under Investigation by Universities/Institutes 19

Kidney Transplant Rejection - Companies Involved in Therapeutics Development 20

Alexion Pharmaceuticals Inc 20

Amgen Inc. 21

Amyndas Pharmaceuticals LLC 22

Angion Biomedica Corp. 23

Apellis Pharmaceuticals Inc 24

Astellas Pharma Inc. 25

Bio-inRen 26

Biogen Inc 27

Catalyst Biosciences, Inc. 28

Corline Biomedical AB 29

CSL Limited 30

Digna Biotech, S.L. 31

GlaxoSmithKline Plc 32

Grifols, S.A. 33

Hansa Medical AB 34

Kyowa Hakko Kirin Co., Ltd. 35

Mabtech Limited 36

Magnus Life Ltd 37

Noorik Biopharmaceuticals AG 38

Novartis AG 39

Opsona Therapeutics Limited 40

OSE Immunotherapeutics 41

Pharmicell Co., Ltd. 42

Pharming Group N.V. 43

Prolong Pharmaceuticals, LLC 44

Quark Pharmaceuticals, Inc. 45

Shire Plc 46

Tiziana Life Sciences Plc 47

Kidney Transplant Rejection - Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Target 49

Assessment by Mechanism of Action 51

Assessment by Route of Administration 53

Assessment by Molecule Type 55

Drug Profiles 57

albumin (human) - Drug Profile 57

AMY-101 - Drug Profile 58

APL-2 - Drug Profile 60

AS-2521780 - Drug Profile 62

basiliximab biobetter - Drug Profile 63

BB-3 - Drug Profile 64

belimumab - Drug Profile 68

bleselumab - Drug Profile 74

BRN-1889 - Drug Profile 75

C1 esterase inhibitor (human) - Drug Profile 76

C1 esterase inhibitor (human) - Drug Profile 81

C1 esterase inhibitor (recombinant) - Drug Profile 83

Cardiotrophin-1 - Drug Profile 91

carfilzomib - Drug Profile 93

CB-2782 - Drug Profile 105

Cellgram for Kidney Transplantation - Drug Profile 106

Cellular Immunotherapy for Kidney Transplantation - Drug Profile 107

Cellular Immunotherapy for Kidney Transplantation - Drug Profile 108

Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile 109

CFZ-533 - Drug Profile 110

eculizumab - Drug Profile 112

EFFI-7H - Drug Profile 121

FCR-001 - Drug Profile 123

foralumab - Drug Profile 125

FR-104 - Drug Profile 126

FX-06 - Drug Profile 129

lefluonomide - Drug Profile 131

Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 132

Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile 134

MRX-109 - Drug Profile 135

N-003 - Drug Profile 136

OPN-305 - Drug Profile 137

QPI-1002 - Drug Profile 139

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 142

Renaparin - Drug Profile 146

rituximab - Drug Profile 147

Sanguinate - Drug Profile 152

tiomolibdate diammonium - Drug Profile 154

TNT-009 - Drug Profile 155

Kidney Transplant Rejection - Dormant Projects 157

Kidney Transplant Rejection - Discontinued Products 160

Kidney Transplant Rejection - Product Development Milestones 161

Featured News & Press Releases 161

Appendix 170

Methodology 170

Coverage 170

Secondary Research 170

Primary Research 170

Expert Panel Validation 170

Contact Us 170

Disclaimer 171

List of Tables

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H2 2016 12

Number of Products under Development for Kidney Transplant Rejection – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2016 22

Kidney Transplant Rejection – Pipeline by Alexion Pharmaceuticals Inc, H2 2016 23

Kidney Transplant Rejection – Pipeline by Amgen Inc., H2 2016 24

Kidney Transplant Rejection – Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 25

Kidney Transplant Rejection – Pipeline by Angion Biomedica Corp., H2 2016 26

Kidney Transplant Rejection – Pipeline by Apellis Pharmaceuticals Inc, H2 2016 27

Kidney Transplant Rejection – Pipeline by Astellas Pharma Inc., H2 2016 28

Kidney Transplant Rejection – Pipeline by Bio-inRen, H2 2016 29

Kidney Transplant Rejection – Pipeline by Biogen Inc, H2 2016 30

Kidney Transplant Rejection – Pipeline by Catalyst Biosciences, Inc., H2 2016 31

Kidney Transplant Rejection – Pipeline by Corline Biomedical AB, H2 2016 32

Kidney Transplant Rejection – Pipeline by CSL Limited, H2 2016 33

Kidney Transplant Rejection – Pipeline by Digna Biotech, S.L., H2 2016 34

Kidney Transplant Rejection – Pipeline by GlaxoSmithKline Plc, H2 2016 35

Kidney Transplant Rejection – Pipeline by Grifols, S.A., H2 2016 36

Kidney Transplant Rejection – Pipeline by Hansa Medical AB, H2 2016 37

Kidney Transplant Rejection – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 38

Kidney Transplant Rejection – Pipeline by Mabtech Limited, H2 2016 39

Kidney Transplant Rejection – Pipeline by Magnus Life Ltd, H2 2016 40

Kidney Transplant Rejection – Pipeline by Noorik Biopharmaceuticals AG, H2 2016 41

Kidney Transplant Rejection – Pipeline by Novartis AG, H2 2016 42

Kidney Transplant Rejection – Pipeline by Opsona Therapeutics Limited, H2 2016 43

Kidney Transplant Rejection – Pipeline by OSE Immunotherapeutics, H2 2016 44

Kidney Transplant Rejection – Pipeline by Pharmicell Co., Ltd., H2 2016 45

Kidney Transplant Rejection – Pipeline by Pharming Group N.V., H2 2016 46

Kidney Transplant Rejection – Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 47

Kidney Transplant Rejection – Pipeline by Quark Pharmaceuticals, Inc., H2 2016 48

Kidney Transplant Rejection – Pipeline by Shire Plc, H2 2016 49

Kidney Transplant Rejection – Pipeline by Tiziana Life Sciences Plc, H2 2016 50

Assessment by Monotherapy Products, H2 2016 51

Number of Products by Stage and Target, H2 2016 53

Number of Products by Stage and Mechanism of Action, H2 2016 55

Number of Products by Stage and Route of Administration, H2 2016 57

Number of Products by Stage and Molecule Type, H2 2016 59

Kidney Transplant Rejection – Dormant Projects, H2 2016 160

Kidney Transplant Rejection – Dormant Projects (Contd..1), H2 2016 161

Kidney Transplant Rejection – Dormant Projects (Contd..2), H2 2016 162

Kidney Transplant Rejection – Discontinued Products, H2 2016 163

List of Figures

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H2 2016 12

Number of Products under Development for Kidney Transplant Rejection – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 51

Number of Products by Top 10 Targets, H2 2016 52

Number of Products by Stage and Top 10 Targets, H2 2016 52

Number of Products by Top 10 Mechanism of Actions, H2 2016 54

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 54

Number of Products by Routes of Administration, H2 2016 56

Number of Products by Stage and Routes of Administration, H2 2016 56

Number of Products by Top 10 Molecule Types, H2 2016 58

Number of Products by Stage and Top 10 Molecule Types, H2 2016 58

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports